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The highly efficacious live-attenuated 17D yellow fever (YF) vaccine is occasionally
associated with rare life-threatening adverse events. Modified vaccinia virus Ankara
(MVA), a non-replicating poxvirus, has been used as a vaccine platform to safely deliver
various antigens. A MVA-based YF vaccine (MVA-BN-YF) was tested with and without a
non-mineral oil adjuvant in a hamster model of lethal YF disease and protective efficacy
of this vaccine was compared with the 17D vaccine. The vaccine candidate MVA-BN-YF
generated a protective response in hamsters infected with YFV that was comparable to
protection by the live 17D vaccine. Similar levels of neutralizing antibody were observed
in animals vaccinated with either vaccine alone or vaccine with adjuvant. Significant
improvement in survival, weight change, and serum alanine aminotransferase levels were
observed in vaccinated hamsters when administered 42 and 14 days prior to challenge
with Jimenez YF virus (YFV). Neutralizing antibodies induced by MVA-BN-YF were transferred to naïve hamsters prior to virus challenge. Passive administration of neutralizing
antibody 24 h prior to virus infection resulted in significantly improved survival and weight
change. A trend toward reduced liver enzyme levels was also observed. MVA-BN-YF,
therefore, represents a safe alternative to vaccination with live-attenuated YFV.
Keywords: yellow fever, 17D, passive immunization, hamster, modified vaccinia virus Ankara, neutralizing
antibodies

INTRODUCTION
Yellow fever (YF), a hemorrhagic disease with jaundice, occurs throughout endemic areas of South
America and Africa (1, 2). The etiologic agent, YF virus (YFV) is a mosquito-born flavivirus. The
development of a live-attenuated vaccine in the early twentieth century significantly decreased
the incidence of YF (3). The live-attenuated 17D vaccine, supplied by seven manufacturers, is
currently used to protect travelers and also in childhood vaccination programs in many affected
countries, with millions of doses distributed annually (4). Extensive use of this vaccine to combat
a recent emergence event in Angola strained the supply of vaccine worldwide and demonstrated
some limitation of availability and accessibility of the 17D vaccines (5), suggesting a need for an
alternative vaccine. The virus also continues to emerge in new areas, including a 2017 outbreak in
Brazil (6) and tens of millions of people could soon be at risk of an urban YF outbreak (7).
Serious adverse events, such as yellow fever vaccine-associated viscerotropic disease (YEL-AVD)
and neurotropic disease (YEL-AND), have been reported after vaccination with the 17D vaccine.
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Incidences of YEL-AVD and YEL-AND in the United States are
reported as 0.4 and 0.8 per 100,000 vaccinations, respectively (8).
YEL-AVD can be quite severe with a case fatality rate of 65% (9).
Moreover, incidence rates of adverse events are much higher in
infants and the elderly (CDC Yellow Book, 2012). Despite the
infrequency of adverse events, these considerations have sti
mulated efforts to develop safer YF vaccines.
The modified vaccinia virus Ankara (MVA) is a highly
attenuated vaccinia virus strain that is non-replicating in humans.
It has been used extensively as an antigen delivery vector. More
over, MVA (MVA-BN®/IMVANEX®/IMVAMUNE®) has been
licensed as safer smallpox vaccine in Europe and Canada. There
is an extensive safety record of MVA in various vaccine platform
applications (10–13). We have developed an MVA-vectored YF
vaccine expressing the poly-protein PreM-E of YFV. In mice,
the vaccine was shown to induce neutralizing antibodies (nAbs)
that were increased by a non-mineral oil adjuvant (unpublished
observation), but efficacy could not be tested in this model.
Challenge of hamsters with the adapted Jimenez strain of
YFV causes viscerotropic disease after IP inoculation that is
similar to disease in humans (14, 15). This model has been used
in the evaluation of both antiviral interventions (16–19) and vaccines (20, 21). We have evaluated immunogenicity and efficacy
of MVA-BN vectored YF and the approved live 17D vaccines in
this model. Moreover, protective levels of nAb present after vaccination with MVA-BN YF were tested in naïve hamsters upon
passive transfer. The results of these studies provide proof of
principle for advancement of this investigational vaccine toward
clinical trials.

Tesh and colleagues (15). A seed stock was prepared from livers
of hamsters, removed 3 days after virus injection and homogenized in a 2× volume of sterile phosphate-buffered saline. This
virus stock had a titer of 106.0 50% cell culture infectious doses
(CCID50)/mL. Hamsters were challenged IP with 0.2 mL of a 10−4
dilution of virus stock (20 CCID50/animal).

Vaccine

MVA-BN YF was prepared by inserting the coding region of preM
and E that are based on the naturally occurring sequence of YFV
(NCBI Accession No NC_002031) into the MVA-BN® backbone.
The virus was propagated in primary chicken embryo fibroblast
cells in serum-free conditions. Montanide (Montanide™ ISA
720 VG manufactured by SEPPIC S.A., France) was used as a
non-mineral oil adjuvant mixed with MVA-BN-YF to obtain a
stable emulsion.
YF-VAX® (Sanofi Pasteur, Swiftwater, PA, USA) 17D YFV
was obtained as a lyophilized powder and was suspended in the
manufacturer-supplied buffer. A 1:10 dilution of the vaccine was
prepared and animals were vaccinated with > 1.0 × 104 plaque
forming units (pfu) 14 days prior to virus challenge.

Neutralization Tests

Antibody levels in serum were quantified using the PRNT50 as
previously described (21). Briefly, samples of test sera were heatinactivated (56°C, 30 min), serial diluted (twofold), and mixed
with an equal volume of YF 17D virus containing 50–70 pfu,
incubated for 16–20 h at 2–8°C, and inoculated onto Vero76
monolayers grown in 12-well plates. Monolayers were covered
with an overlay medium (0.85% methylcellulose in DMEM with
10% fetal bovine serum) after adsorption for 1 h at 37°C. Plates
were fixed and stained with crystal violet-formaldehyde after
5 days incubation at 37°C. The endpoint was the highest dilution
of serum inhibiting plaques by 50% or more when compared with
virus controls.

MATERIALS AND METHODS
Animals

Female golden hamsters (Mesocricetus auratus) with an average
weight of 100 g were obtained from Charles River Laboratories
(Wilmington, MA, USA). Following a 48-h quarantine and 5-day
acclimation period, animals were randomly assigned to groups
and individually marked with ear tags. All work with animals
was performed in the Biosafety Level 3 area of the AAALACaccredited Laboratory Animal Research Center at Utah State
University (USU). Hamsters were cared for under an animal
use protocol approved by the Institutional Animal Care and Use
Committee Laboratory Animals (IACUC) at USU.

Serum Aminotransferase Assays

Serum was collected via ocular sinus bleed on 6 dpi. Alanine aminotransferase (ALT) (SGPT) reagent (Teco Diagnostics, Anaheim,
CA, USA) was used, and the protocol was altered for use in
96-well plates as described previously (14). The aminotransferase
concentrations were determined per manufacturer’s instructions.

Infectious Cell Culture Assay

Test serum samples collected 4 dpi were serially diluted and
added to Vero 76 cells. Ten days later, CPE was used to identify
the endpoint of infection. Four replicates were used to calculate
the CCID50/mL.

Viruses

YF virus 17D was prepared by passaging in a monolayer culture
of Vero cells and by harvesting cell culture fluid at the appearance
of cytopathic effects (CPE). The virus was incubated overnight
at 4°C followed by quantification by plaque assay in Vero76 cells
grown in 12-well plates under methylcellulose overlay. After
5 days of incubation at 37°C and 5% CO2, plates were fixed and
stained with 0.3% crystal violet-formaldehyde and plaques were
counted.
The Jimenez strain (South American genotype I, isolated in
Panama, 1974) was used for hamster challenge studies. The virus
was adapted by serial passage in hamster liver, as described by
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Protective Efficacy of MVA-BN YF

Hamsters were randomly assigned to groups of 10–15 animals.
Animals were immunized s.c. with MVA-BN YF ± adjuvant
on −42 and −14 dpi or s.c. on −14 dpi with YF-VAX. A 10−4
dilution (102.0 CCID50/mL) of the virus was prepared in minimal
essential media. Hamsters were challenged on day 0 with Jimenez
YFV. Serum was collected on −1, 4, and 6 dpi from all surviving
hamsters for quantification of neutralizing antibody, serum virus,
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and ALT, respectively. Hamsters were observed at least twice
daily for mortality, and weights were taken daily from 0 to 8 dpi
to track weight change. Early euthanasia criteria included lying
prone, lack of motility or non-responsiveness. Animals that were
humanely euthanized were recorded as a mortality event on the
following day, as opposed to animals naturally succumbed to viral
disease between mortality checks, which were recorded on the
day they were found.

pooled by treatment group and used in the subsequent passive
Ab transfer study described below.
Vaccination with MVA-BN-YF ± adjuvant administered −42
and −14 days prior to virus challenge resulted in significant
(p < 0.001) protection through the end of the study (Figure 1B;
Table 1). In fact, complete survival was observed in all vac
cinated animals, including those vaccinated with YF-VAX,
when compared with 40 and 20% survival of vehicle control
groups that were injected at the same time as vaccine with TBS
or TBS + adjuvant as vehicle control, respectively (Figure 1B;
Table 1).
Serum ALT was significantly reduced to baseline levels in all
animals vaccinated with MVA-BN YF or YF-VAX when compared with respective controls that showed elevated levels of the
liver enzyme, a typical read-out for YFV infection (Figure 1C;
Table 1). Animals vaccinated with MVA-BN YF ± adjuvant or
with YF-VAX had a similar weight gain to uninfected control
animals (Figure 1D). Vehicle-vaccinated animals infected with
YFV experienced weight loss beginning 5 dpi, which continued
to mortality and is similar to previous results in this model. Some
weight loss was observed on day 5 in sham-infected animals
treated with TBS + adjuvant, but this group gained weight after
that time. Significant improvement in weight gain between 3
and 6 dpi was observed in hamsters immunized with MVA-BN
YF ± adjuvant or with YF-VAX (Table 1).

Passive Antibody Transfer

Serum samples collected during the vaccination study were
used in passive immunization studies. Serum pools were diluted
1:10–1:100. A volume of 0.5 mL of each serum dilution was
administered IP to groups of 10 hamsters 24 h prior to virus
challenge. Serum was collected just prior to virus challenge to
determine the level of nAb present in the serum at that time.
Twenty-four hours after antibody treatment, animals were challenged with virus and followed for mortality, weight change,
ALT levels, and viremia. A group treated with immune serum
(IS) from animals vaccinated with MVA-BN YF was shaminfected and served as a toxicity control. An additional group
of untreated and uninfected animals was included as normal
controls. Serum was collected just prior to virus challenge to
determine the nAb titer of each group 1 day after treatment.
Serum samples were collected from the retro-orbital sinus 4 and
6 days after challenge for the assessment of virus titer and serum
ALT levels, respectively.

Passive Neutralizing Antibody Protection
Studies

Statistical Methods

Naïve hamsters were treated i.p. with 1:10 or 1:100 dilutions of
pooled IS collected on day 49, either from animals immunized
with two injections (day 0 and 28) of MVA-BN YF emulsified
in Montanide adjuvant, or from animals receiving one injection of YF-VAX (day 28) (Table 2). One day after IS transfer,
animals were challenged with YFV. A serum sample was taken
from each animal 4 h prior to virus challenge to determine the
neutralizing Ab present in the serum at the time of infection.
All of the animals treated with a 1:10 dilution of IS from the
MVA-BN YF group had detectable (≥1 log10 PRNT50) neutralizing
Ab titers present in the serum 24 h after treatment (Figure 2A;
Table 3). The average PRNT50 for animals treated with 1:10 diluted
MVA-BN YF pooled serum was significantly (p < 0.01) higher
than that of animals treated with IS from placebo-vaccinated
animals (Figure 2A; Table 2). Animals treated with a 1:100 dilution of IS from MVA-BN YF-vaccinated hamsters had PRNT50
levels at or below the level of detection (Table 2).
All but one animal from the 1:10 dilution of serum from
animals vaccinated with YF-VAX had titers above the level of
detection (≥1 log10 PRNT50), but the average was lower than that
of the MVA-BN YF serum and was not significantly different from
placebo treatment (Figure 2A; Table 3). All of the animals in the
group treated with the 1:100 dilution of YF-VAX serum or with
a 1:10 dilution of serum from placebo-vaccinated animals had
neutralizing Ab titers at or below the limit of detection (Table 2).
Neutralizing Ab titers corresponded well with predicted titers
(Table 2). Higher levels of detectable neutralizing Ab also corresponded with increased protection, e.g., in the group treated

Treatment group comparisons for continuous variables (weight
change, ALT, and viremia) were performed by one-way ANOVA
with a Bonferroni multiple comparison post-test analysis comparing the antibody-treated groups to the placebo control group.

RESULTS
Vaccination Studies

Animals were vaccinated s.c. with 1 × 108 TCID50 of MVABN-YF, with or without Montanide adjuvant, 42 and 14 days
prior to challenge with YFV. The approved vaccine YF-VAX
(Sanofi Pasteur) was used as a positive control and was administered s.c. 14 days prior to virus challenge. Daily monitoring of
the animals after immunization revealed no observable adverse
reaction to vaccination. In accordance with accepted correlates
of protection, we quantified nAb titers in the serum of animals
24 h prior to virus challenge. Significantly (p < 0.001) elevated
levels of nAb were observed in the serum of animals vaccinated
with MVA-BN YF ± adjuvant or with YF-VAX when compared
with Tris-buffered saline (TBS) ± adjuvant vaccinated controls
or with normal controls (Figure 1A). There were also significantly (p < 0.05) higher levels of nAb in the serum of animals
vaccinated with MVA-BN YF with and without adjuvant when
compared with those from animals vaccinated with YF-VAX
(Figure 1A). Unexpectedly, an adjuvant effect such as seen
in mice (data not shown) was not detected (Figure 1A). The
remainder of serum collected prior to virus challenge was
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Figure 1 | (A) Log10 plaque reduction neutralization titers to YF virus (YFV) were significantly elevated in hamsters vaccinated with MVA-BN YF ± adjuvant or with
YF-VAX® compared with animals vaccinated with vehicle [Tris-buffered saline (TBS)] ± adjuvant or untreated normal controls (n = 10/group). (B) Vaccination was
protective in animals challenged with YFV and (C) serum levels of alanine aminotransferase on day 6 and (D) time-course weight change was improved in hamsters
immunized with MVA-BN YF or YFVAX® (***p < 0.001, when compared with vehicle).

Table 1 | Efficacy of vaccination with MVA-BN YF on disease in hamsters challenged with YF virus.
Toxicity controls
Treatment

MVA-BN YF
MVA-BN YF + Adj.
YF-VAX
Tris-buffered saline
(TBS) + Adj.
TBS
Norm. controls

Treatment dose,
schedule

1 × 108 TCID50, −42, −14 dpi
1 × 108 TCID50, −42, −14 dpi
>5.5 × 104 pfu, −14 dpi
−42, −14 dpi
−42, −14 dpi
–

Infected, treated

Alive/
total

Serum alanine
aminotransferase
(ALT)a (IU/L) ± SD

Mean wt.
changeb
(g) ± SD

Alive/
total

MDDc ± SD

Serum ALT a
(IU/L) ± SD

Mean wt.
changeb
(g) ± SD

–
3/3
3/3
3/3

–
62.3 ± 9.1
66.4 ± 18.0
57.6 ± 5.9

–
5.0 ± 2.0
4.3 ± 3.1
−0.3 ± 6.1

10/10
10/10
10/10
2/10

>21.0 ± 0.0
>21.0 ± 0.0
>21.0 ± 0.0
8.6 ± 1.3

61.9 ± 5.0
62.8 ± 8.3
58.4 ± 6.6
151.6 ± 57.0

4.8 ± 4.2
4.6 ± 1.9
4.6 ± 2.5
−6.2 ± 7.3

3/3
3/3

62.5 ± 5.8
64.3 ± 2.6

2.3 ± 1.2
5.0 ± 0.0

6/15
–

8.4 ± 1.2
–

156.9 ± 42.3
–

−8.9 ± 7.1
–

Serum ALT levels collected on 6 dpi.
Difference between weight on 3 and 6 days post-virus challenge representing maximal weight change within this study.
c
Mean day to death of animals that succumb to disease during the experimental period of 21 days.
a

b

(p < 0.001) protection to naïve hamsters challenged with YFV as
compared with placebo (Figure 2B). No significant protection
was observed after passive administration of a 1:10 dilution
of serum from animals immunized with YF-VAX, despite a
higher survival rate when compared with placebo (Figure 2B).

with 1:10 dilution of MVA-BN YF serum, further demonstrating
the protective effect of MVA-BN YF vaccination through neutralizing Ab.
Indeed, treatment with the 1:10 dilution of the serum from
the group vaccinated with MVA-BN YF provided significant
Frontiers in Immunology | www.frontiersin.org
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Table 2 | The effect of passively transferred immune serum (IS) from animals vaccinated with MVA-BN YF vaccine or with YF-VAX administered 24 h prior to challenge
with YF virus.
Toxicity controls
Treatment

Dose

MVA-BN YF IS
MVA-BN YF IS
YF-VAX IS
YF-VAX IS
Placebo IS
Norm. controls

1:10
1:100
1:10
1:100
1:10
–

Serum NeutAb
titera

1.1 ± 0.2
<1.0 ± 0.0
1.0 ± 0.1
1.0 ± 0.1
<1.0 ± 0.0

Alive/
total

3/3
–
3/3
–
3/3
3/3

Serum alanine
aminotransferase
(ALT)b (IU/L) ± SD
67 ± 9.0
–
60 ± 6.0
–
73 ± 19
56 ± 6.0

Infected, treated
Mean wt.
changec
(g) ± SD

Alive/total

4.7 ± 2.1
–
6.0 ± 1.0
–
6.0 ± 3.0
4.7 ± 2.1

8/10***
4/10
3/10
1/10
1/15
–

MDDd ± SD

10.0 ± 0.0
8.5 ± 1.0
9.0 ± 1.5
8.4 ± 0.9
9.3 ± 1.5
–

Serum ALTb
(IU/L) ± SD
88 ± 34
206 ± 82
162 ± 92
170 ± 89
169 ± 99
–

Mean wt.
changec
(g) ± SD
5.3 ± 3.4**
−7.5 ± 5.1
−4.9 ± 5.3
−7.5 ± 6.9
−4.9 ± 8.3
–

Average log10 neutralizing antibody titer of serum collected 4 h prior to virus challenge and quantified by PRNT50.
Serum ALT levels collected on 6 dpi.
c
Difference between weight on 3 and 6 days post-virus challenge representing maximal weight change within this study.
d
Mean day to death of animals that succumb to disease during the experimental period of 21 days.
***p < 0.001, **p < 0.01, when compared with placebo treatment.
a

b

Figure 2 | (A) Passive administration of serum from hamsters vaccinated with MVA-BN YF or YF-VAX® resulted in low levels of neutralizing Ab in naïve hamsters
(n = 10/group) present 24 h after treatment. (B) Survival of hamsters after passive administration of serum from vaccinated hamsters. Passive transfer was only
significantly protective in hamsters receiving a 1:10 dilution of serum from hamsters vaccinated with MVA-BN YF. (C) Serum alanine aminotransferase on 6 days
post challenge for individual hamsters passively immunized with various dilutions of immune serum generated after immunization with MVA-BN YF or YF-VAX®.
(D) Time-course weight change from 0 to 8 dpi.

(Figure 2C). Typically, ALT and mortality are generally correlative in this model (14), but in this study, ALT levels in animals
treated with IS from placebo-vaccinated animals were widely
distributed and diminished statistical power for this parameter.

Hamsters treated with the 1:10 dilution of MVA-BN YF IS also
had lower serum ALT titer than all other groups, although this difference was not significant (p > 0.05) when compared with levels
in animals treated with serum from placebo-vaccinated animals
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model of YF was used to assess the minimal protective level
of neutralizing Ab elicited by the 17D YF vaccine, which was
determined to be ≥0.7 log 10 neutralization index of ≥0.7
(28). Natural infection or effective vaccination will elicit the
production of neutralizing antibody, which will persist in the
serum, protecting from subsequent challenge with the same
virus or serotype. We have also demonstrated protection after
immunization with an investigational vaccine in a hamster
model of YFV infection and demonstrated neutralizing antibody as a correlate of protection (20, 21). Significantly elevated
levels of neutralizing antibody were observed in hamsters vaccinated with MVA-BN YF, which were protective in passive
administration studies. Typically, MVA-BN-based vaccines
provide transient and localized expression of the gene of interest in animal models. We anticipate that preM and E expression
will be inactive 2 weeks after vaccination with MVA-BN YF.
Protection observed in these studies would be due to elicited
immune responses as a result of vaccination.
Vaccination with YF-VAX was included as a control,
although the different nature of YF-VAX and MVA-BN YF
precluded a direct comparison. The currently approved
YF-VAX is a live-attenuated vaccine that confers protection after
a single dose, while MVA-BN YF is replication incompetent and
has a relatively short period of antigen expression and would
likely require a booster vaccination in a clinical setting. The
potential disadvantage of a required booster vaccination is, in
our view, compensated by a very good safety profile of the nonreplicative MVA-BN YF and precludes the adverse events that
are associated with YF-VAX. Previous studies demonstrated
a greater degree of stimulation of neutralizing Ab production
after immunization with YF-VAX, but a greater vaccine dose
(>4.7 log10 pfu) was used in these studies (20, 21). The predicted
protective value of a PRNT50 value of 40 (1.6 log10 PRNT50) was
also higher than what was observed in this study, but this is
likely well above functional protective levels and other studies indicate that Ab levels >1.0 log10 PRNT50 are protective in
vaccinee (29). The addition of the non-mineral oil Montanide
to MVA-BN YF did not increase antibody titers compared to
the non-adjuvanted vaccine. This was in contrast to previous
unpublished findings in BALB/c mice. However, differences
in the mouse were greater after a single vaccination and the
hamster studies reported here used a prime-boost vaccination
schedule only.
Taken together, vaccination of hamsters with an MVA-based
YF vaccine provided full protection that was comparable to the
licensed 17D YF vaccine, and this protection could be transferred to
naïve hamsters through serum, confirming that induced neutra
lizing antibodies are a correlate of protection. MVA-BN YF may
represent a safe alternative to 17D YF vaccines.

Table 3 | Neutralizing antibody titers present in serum 24 h after treatment with
a 1:10 dilution of immune serum.
Log10 PRNT50a (survival-y/nb)

Animal
number

Treatment

1:10 MVA-BN YF

1:10 YF-VAX

1:10 Placebo

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

1.3 (y)
1.0 (y)
1.0 (n)
1.3 (y)
1.0 (n)
1.3 (y)
1.0 (y)
1.0 (y)
1.0 (y)
1.3 (y)

1.0 (y)
1.3 (n)
1.0 (n)
1.0 (n)
1.0 (n)
1.0 (n)
1.0 (n)
<1.0 (y)
1.0 (y)
1.0 (n)

<1.0 (n)
1.0 (n)
<1.0 (n)
<1.0 (n)
<1.0 (n)
<1.0 (n)
<1.0 (y)
<1.0 (n)
<1.0 (n)
<1.0 (n)
<1.0 (n)
1.0 (n)
1.0 (n)
1.0 (n)
<1.0 (n)

The eventual survival (y) or mortality (n) through 21 dpi is indicated in parentheses.
a
The log10 50% of control.
b
Did the animal survive (yes or no)?

Improved weight change after 4 dpi was observed in hamsters
in the group receiving the 1:10 dilution of serum from MVA-BN
YF immunized animals (Figure 2D). This weight gain was
similar to that of sham-infected groups. Indeed, the difference
in weight between 3 and 6 dpi was significantly (p < 0.01)
improved in animals treated with 1:10 MVA-BN YF serum
group when compared with infected hamsters treated with IS
from placebo-vaccinated groups (Table 2). All other groups had
weight loss similar to that of animals treated with serum from
vehicle-vaccinated animals.

DISCUSSION
The investigational YFV vaccine MVA-BN YF provided protection in a hamster model of disease, as indicated by significant
improvement in survival, weight change, and liver enzyme levels
in the blood when compared with placebo vaccination. Protection
corresponded with induced neutralizing Ab titers, which was
demonstrated by passive transfer studies. Although millions of
doses of the currently approved 17D-based vaccine have been used
to protect from YFV infection and disease, a recent outbreak in
Angola demonstrated the limitation of the global stockpile of this
vaccine and underscores the potential need for the development
of a safe and effective vaccine. Use of MVA-BN YF would improve
some aspects of the current YFV vaccine, including reducing or
eliminating rare adverse events associated with current vaccines
(22). Although MVA-BN YF utilizes a live-attenuated virus, this
replication deficient virus demonstrated a high level of safety and
immunogenicity in around 7,000 vaccinated individuals (23),
even in fully immune compromised mice and primates (24–26).
The results reported herein suggest further testing toward clinical
development is warranted.
The accepted immune correlate of protection against YF
is neutralizing antibodies (27). A lethal primate challenge
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